Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Advanced Stage
100%
Phase I Study
100%
Bortezomib
100%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
37%
Objective Response
25%
Response Rate
25%
Adenocarcinoma
25%
Inhibitor Therapy
25%
Non-small Cell Lung Cancer (NSCLC)
12%
Disease Progression
12%
Overall Survival
12%
Anticancer Activity
12%
Patient Characteristics
12%
Diarrhea
12%
Disease Stabilization
12%
Accruals
12%
4-cycle
12%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
12%
Cytotoxic Chemotherapy
12%
Protease Inhibitors
12%
Low Response
12%
Early Phase Clinical Trials
12%
Median Progression-free Survival
12%
Medicine and Dentistry
Malignant Neoplasm
100%
Bortezomib
100%
Lung Alveolus Cell Carcinoma
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
37%
Adenocarcinoma
25%
Diseases
25%
Clinical Trial
12%
Overall Survival
12%
Diarrhea
12%
Antineoplastic Activity
12%
Non Small Cell Lung Cancer
12%
Progression Free Survival
12%
Disease Exacerbation
12%
Oncology
12%
Cytotoxic Chemotherapy
12%
Patient Characteristics
12%
Proteasome Inhibitor
12%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Bortezomib
100%
Lung Alveolus Cell Carcinoma
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
37%
Adenocarcinoma
25%
Diseases
25%
Clinical Trial
12%
Disease Exacerbation
12%
Progression Free Survival
12%
Non Small Cell Lung Cancer
12%
Overall Survival
12%
Cytotoxic Chemotherapy
12%
Diarrhea
12%
Proteasome Inhibitor
12%